SEC Company Response from Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — Jun 19, 2019
Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: June 19, 2019 · CIK: 0000715446 · Accession: 0001513162-19-000158
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232067
Letter
VIA EDGAR Office of Financial Services Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed June 11, 2019 File No. 333-232067
Dear Mr. Alper:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Friday, June 21, 2019, or as soon as thereafter practicable.
Very truly yours,
/s/ Dr. Amit Kumar
Show Raw Text
CORRESP
1
filename1.htm
Company Acceleration Request
ANIXA BIOSCIENCES, INC.
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
June 19, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Office of Financial Services
100 F Street, N.E.
Mail Stop 4628
Washington, DC 20549
Attn: Ronald Alper
Re:
Anixa Biosciences, Inc.
Registration Statement on Form S-3
Filed June 11, 2019
File No. 333-232067
Dear Mr. Alper:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Friday, June 21, 2019, or as soon as thereafter practicable.
Very truly yours,
/s/ Dr. Amit Kumar
Dr. Amit Kumar
Chairman, President and Chief Executive Officer
cc:
Ellenoff Grossman & Schole LLP